Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) announced today its plans to release its second quarter 2023 financial results on Monday, August 14, 2023, after market close. Subsequently, the Company will host a conference call at 5:00 p.m. (Eastern Time) to review the results and provide an overview of its recent progress and notable milestones. Vivos is a medical technology company committed to revolutionizing diagnostics and treatments for patients with breathing related sleep disorders and dentofacial abnormalities.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is revolutionizing the way we treat common breathing and sleep issues like obstructive sleep apnea (OSA) and snoring in adults. Through their innovative diagnostic and treatment methods, they have developed the Vivos Method which is a clinically effective, non-surgical, non-invasive, non-pharmaceutical and cost-efficient solution for treating mild to moderate OSA, and it has been proven effective in over 40,000 patients treated worldwide by more than 1800 trained dentists. With the Vivos Method, mild to moderate OSA can finally be combated without resorting to surgery or harmful drugs.
The Vivos Method is a revolutionary way for individuals to manage conditions associated with mild-to-moderate Obstructive Sleep Apnea (OSA). It utilizes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols to open airway space and alter the size, shape and position of soft tissues that are significant causes of OSA.
Best of all, individuals utilizing the Vivos Method have seen their Apnea Hypopnea Index scores drop dramatically. Furthermore, Vivos provides SleepImage diagnostic technology under the VivoScore program for home sleep testing in both adults and children, complemented by its Vivos Integrated Practice (VIP) program that offers dentists the necessary information and services to use The Vivos Method successfully.
Cautionary Note Regarding Forward-Looking Statements
Vivos is looking forward to the public offering described herein, and promises to remain committed to its shareholders. Our team has identified several potential risks and uncertainties including, but not limited to, factors outlined in our SEC filings. We encourage all of our investors to visit www.sec.gov to view those filings free of charge. Expect changes in Vivos’ expectations and updates to our forward-looking statements as new events, conditions, and circumstances occur. Together we can make the future bright!